Psoriatic arthritis (PsA) goes beyond the skin and the joint.
According to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), there are six key domains of disease activity that should guide the physician in treatment decisions (Fig. 1).1
The efficacy of Secukinumab (Scapho®) has been studied across all six domains.
In the FUTURE 5 Study, Secukinumab (Scapho®) was superior to placebo in terms of ACR 20, ACR 50, PASI 75, and PASI 90 response, demonstrating efficacy across the skin and joint as early as in Week 4. Moreover, resolution of enthesitis and dactilytis was seen up to Week 24.2
In the TRANSFIGURE Study, Secukinumab (Scapho®) demonstrated sustained efficacy among patients with moderate-to-severe plaque psoriasis with signifcant nail involvement.3
In the MAXIMISE Study, Secukinumab (Scapho®) provided significant improvement in the signs and symptoms of axial disease versus placebo in patients with PsA and axial manifestations with inadequate response to NSAIDs. Patients given Secukinumab (Scapho®) had signifcantly improved ASAS 20 response versus placebo at Week 12.4
Overall, these studies show that Secukinumab (Scapho®) demonstrates efficacy across all six domains in achieving comprehensive treatment goals in PsA.
For more information on Secukinumab (Scapho®), read the full prescribing information here.
Acronyms:
· GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
· ACR: American College of Rheumatology
· PASI: Psoriasis Area and Severity Index
· ASAS: Assessment of Spondyloarthritis International Society
· NSAIDs: Non-Steroidal Anti-Inflammatory Drugs
References:- Alavi et al. (2023). Charting the Course Toward Improved Patient Outcomes in Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA). Available at: https://www.hmpgloballearningnetwork.com/site/derm/charting-course-towar....
- Mease at al. (2018). FUTURE 5 Study. Ann Rheum Dis. 77:890-897.
- Reich et al. (2021). TRANSFIGURE Study. Br J Dermatol. 184(3):425-436.
- Baraliakos et al. (2020). MAXIMISE Study. Ann Rheum Dis. 80:582-590